Enhancement by oxiracetam of passive avoidance improvement induced by the presynaptic muscarinic antagonist secoverine in mice

Martine Ammassari-Teule, Claudio Castellano, Mario Sansone

Research output: Contribution to journalArticle

Abstract

Post-trial administration of secoverine (0.5, 1 and 2.5 mg/kg), a presynaptic muscarinic blocker, improved retention in mice tested in a passive avoidance task. The nootropic drug oxiracetam (50 mg/kg), given before both acquisition and retention trial, had no effect alone, but significantly enhanced secoverine improving effects. Performance improvements were also found in combining ineffective doses of the two compounds. Even if not necessarily through a direct and specific action, oxiracetam might activate cholinergic function. Thus, performance improvements resulting from the combination of oxiracetam and secoverine may be due to a simultaneous activation of different cholinergic mechanisms.

Original languageEnglish
Pages (from-to)93-95
Number of pages3
JournalBehavioural Brain Research
Volume47
Issue number1
DOIs
Publication statusPublished - Mar 15 1992

Keywords

  • Mouse
  • Oxiracetam
  • Passive avoidance
  • Secoverine

ASJC Scopus subject areas

  • Behavioral Neuroscience

Fingerprint Dive into the research topics of 'Enhancement by oxiracetam of passive avoidance improvement induced by the presynaptic muscarinic antagonist secoverine in mice'. Together they form a unique fingerprint.

  • Cite this